Keytruda’s Catch-22 Situation In India Amid Compliance Questions
Executive Summary
Merck & Co’s immuno-oncology therapy Keytruda appears be facing a rather paradoxical situation in India, after an expert panel noted that the US multinational had failed to comply with Phase IV study requirements pertaining to the product in the country.